These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 78252)

  • 1. Propranolol therapy for secondary hyperparathyroidism in uraemia.
    Fournier A; Coevoet B; de Fremont JF; Gueris J; Caillens G; Desplan C; Calmette C; Moukhtar MS
    Lancet; 1978 Jul; 2(8079):50-1. PubMed ID: 78252
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of propranolol and atenolol in the control of hyperparathyroidism in uremia.
    Makdassi R; Andrejak M; Morinière P; Sebert JL; Decourt S; Guéris J; Coevoet B; Fournier A
    Adv Exp Med Biol; 1982; 151():667-76. PubMed ID: 7180669
    [No Abstract]   [Full Text] [Related]  

  • 3. Blockers of beta and H2 receptors and secondary hyperparathyroidism in uraemia.
    Makdassi R; Decourcelle PH; Moriniere P; Coevoet B; de Fremont JF; Kassouf J; Roussel A; Gheerbrand JD; Andrejak M; Fournier A
    Proc Eur Dial Transplant Assoc; 1981; 18():642-7. PubMed ID: 7329992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of propranolol and metoprolol on parathyroid hormone and calcitonin secretions in uraemic patients.
    Coevoet B; Desplan C; Sebert JL; Makdassi R; Andrejak M; Gheerbrant JD; Tolani M; Calmette C; Moukhtar MS; Fournier A
    Br Med J; 1980 Jun; 280(6228):1344-6. PubMed ID: 7388535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute effects of propranolol and metoprolol on plasma concentrations of parathyroid hormone and calcitonin in uraemic patients.
    Coevoet B; Desplan C; Sebert JL; Makdassi R; Gherbrand JD; Tolani M; Calmette C; Moukhtar MS; Fournier A
    Proc Eur Dial Transplant Assoc; 1979; 16():649-55. PubMed ID: 44916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Propranolol in uraemic osteodystrophy.
    Eastwood JB
    Lancet; 1979 Feb; 1(8112):386-7. PubMed ID: 85038
    [No Abstract]   [Full Text] [Related]  

  • 7. Histamine H2 receptor blockade in patients with hyperparathyroidism.
    Cunningham J; Segre G; Slatopolsky E
    Am J Nephrol; 1984; 4(4):205-7. PubMed ID: 6089561
    [No Abstract]   [Full Text] [Related]  

  • 8. [Cinacalcet--a new drug for the treatment of secondary hyperparathyroidism in patients with uraemia, parathyroid cancer or primary hyperparathyroidism].
    Vestergaard P; Nielsen LR; Mosekilde L
    Ugeskr Laeger; 2006 Jan; 168(1):29-32. PubMed ID: 16393559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Propranolol in uraemic osteodystrophy.
    Brancaccio D; Galmozzi C; Casati S; Ponticelli C
    Lancet; 1978 Oct; 2(8096):940. PubMed ID: 81949
    [No Abstract]   [Full Text] [Related]  

  • 10. [Calcimimetics and secondary uremic hyperparathyroidism. The Danish Society of Nephrology].
    Ølgaard K
    Ugeskr Laeger; 2003 Mar; 165(12):1245. PubMed ID: 12701295
    [No Abstract]   [Full Text] [Related]  

  • 11. [Oral calcimimetics on secondary hyperparathyroidism of uremia.].
    Imanishi Y
    Clin Calcium; 2017; 27(4):561-566. PubMed ID: 28336833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New therapies for uremic secondary hyperparathyroidism.
    Torres PU; Prié D; Beck L; Friedlander G
    J Ren Nutr; 2006 Apr; 16(2):87-99. PubMed ID: 16567265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parathyroid acidosis in uraemia.
    Muldowney FP; Donohoe JF; Carroll DV; Powell D; Freaney R
    Q J Med; 1972 Jul; 41(163):321-42. PubMed ID: 5072056
    [No Abstract]   [Full Text] [Related]  

  • 15. [Evidence, in uremic man, of the role of beta 2 adrenergic receptors in the secretion of parathyroid hormone and calcitonin (author's transl)].
    Coevoet B; Lambrey G; de Frémont JF; Hardin JM; Desplan C; Calmette C; Makdassi R; Andrejak M; Moukhtar MS; Fournier A
    Nephrologie; 1980; 1(1):34-6. PubMed ID: 6272143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary and secondary uraemic hyperparathyroidism: from initial clinical observations to recent findings.
    Drüeke TB
    Nephrol Dial Transplant; 1998 Jun; 13(6):1384-7. PubMed ID: 9641165
    [No Abstract]   [Full Text] [Related]  

  • 17. Optimal paricalcitol starting dose for parathyroid hormone suppression in secondary hyperparathyroidism.
    Mansour J; Shahapuni I; Mailliez S; Aghai R; Fournier A
    Nat Clin Pract Nephrol; 2007 Apr; 3(4):E2; discussion E3. PubMed ID: 17389886
    [No Abstract]   [Full Text] [Related]  

  • 18. [MIBI and parathyroid gland function in secondary hyperparathyroidism].
    Martín F; Sarró F; Verdú J; González A; Martínez F
    Nefrologia; 2004; 24(4):344-50. PubMed ID: 15455494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tertiary hyperparathyroidism treated by ultrasonically guided percutaneous fine-needle ethanol injection.
    Cintin C; Karstrup S; Ladefoged SD; Joffe P
    Nephron; 1994; 68(2):217-20. PubMed ID: 7830859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The control of hyperphosphataemia in haemodialysis patients.
    Papayianni L; Katopodis K; Kosmanou J; Banioti A; Katsaraki A; Palatzidou M; Prokopiou F; Betsiou V; Siamopoulos KC
    EDTNA ERCA J; 1997; 23(4):25-7. PubMed ID: 9664020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.